Sanara Medtech Inc. · NASDAQ:SMTI
Sanara Medtech — Investor Presentation (November 2022)
10 slides from Sanara Medtech's investor presentation, Nov 30, 2022
Slide 1: Sanara MedTech Overview
Sanara MedTech Overview (Nasdaq: SMTI) sé: Sanarda * MedTech Evidence Based Healing
Slide 2: Disclaimers
Sanara MedTech Disclaimers This presentation contains forward-looking statements that discuss expectations as to future trends, plans, events, results of operations or financial condition, or state other information relating to Sanara MedTech Inc. (the “Company,” “Sanara,” “we,” “our” or “us”). All
Slide 3: Sanara MedTech Overview
Sanara MedTech Sanara MedTech Overview + Based in Fort Worth, Texas + NASDAQ: SMTI: $303 million market cap as of November 25, 2022 + In Q3 2022, revenues generated by the Company increased 124% compared to the prior year period. + Two main divisions: Surgical wound care (acute settings, implemented
Slide 4: Surgical Wound Opportunity
Surgical Wound Opportunity Strategy is to minimize post-acute care costs Sanara MedTech spital admission and wound care center visi rgical Wound Market o Surgical Wounds are the largest Medicare spend area in wound care totaling $11.7B (including cost of infections)” o 15.3M surgeries in the U.S. ea
Slide 5: Surgical Products
Surgical Products Sanara MedTech Surgical Division Overview * 36 field sales managers ¢ CellerateRX® Surgical sold in 662\ hospitals/ASCs in the TTM * CellerateRX® Surgical sold in hospitals/ASCs across 28 states) in the TTM ¢ CellerateRX® Surgical approved to be sold in 1,714 hospitals/ASCs * Total
Slide 6: Chronic Wound Care Opportunity
Chronic Wound Care Opportunity Pro improved outcomes. What is the Wound Care Industry Missing Today? Early, accurate diagnosis and intervention Comorbidity recognition and management Education / standard of care for primary providers Access to specialty wound care Product and service innovation Valu
Slide 7: Strategic Highlights
Strategic Highlights * Sanara MedTech seeks to offer a complete suite of tools to aid clinicians in any care setting as they treat wounds, leading to better patient outcomes and lower cost to the healthcare system. * The Company’s comprehensive offering positions it well to target both fee-for-servi
Slide 8: Portfolio of MedTech Solutions
Sanara MedTech Portfolio Fed! MedTech Sanara Diagnostics/Treatment Algorithms EMR and Mobile App jal Consult Under development + Novel and disruptive approach to unmet need in the care of skin and chronic wounds + Allows for development of advanced virtual care pathways with scalable patient access
Slide 9: Q3 2022 Financial Highlights
Q3 2022 Financial Highlights Overview + Revenue + For the quarter, the Company generated net revenues of $13.0 million compared to net revenues of $5.8 million for the three months ended September 30, 2021 representing a 124% increase from the prior year period. ¢ Third quarter revenues included $3.
Slide 10: Questions
Questions Sanara MedTech Evidence Based Healing 10
Sanara MedTech — Investor Presentation (November 2022) on 6ix